Pfizer Inc. (NYSE: PFE) Study Shows The Company Gives Equitable Pay to Workers

Pfizer Inc. (NYSE: PFE) has stated for the third time that a compensation expert has recognized that the company offers equitable pay to workers.

This announcement came after a study on gender-based pay worldwide and for U.S minorities. It used bonuses, merit increases, and base pay to assess payment equity. The study also adjusted for location, experience, job level, grade, and role.

The results showed that Pfizer’s compensation for female employees was more than 99.4% of what their colleagues across the globe received. This figure was an increase from 99.3% in 2020. Moreover, its minority employees received a dollar for dollar parity (100%) compared to 99.8% in 2020.

Pfizer previously launched the 2025 Opportunity Parity initiative to increase female and minority representation at senior-level positions. The company has released its results from 2020 and will continue to do so.

Pfizer announces webcast on March

Meanwhile, the company invites investors to a webcast where the Executive Vice President, Chief Digital and Technology Officer from the Truist Securities Life Sciences AI Symposium- Biotech and Tools, Lidia Fonseca, will speak. This webcast will take place on March 1, 2022, at 12.30 pm Eastern Standard Time.

Paxlovid is more available as omicron infection subsides

When omicron infections in the U.S when at an all-time high, it was complicated for pharmacies and hospitals to get their hands in Paxlovid. This drug, which Pfizer developed, was the first line of treatment for COVID-19 infection. The breakthrough oral pill was a game-changer as it would be easier to administer to patients with infections.

The drug has received approval from the Food and Drug Administration (FDA) and the Center for Disease Control and Prevention (CDC). The pill is to be taken for five days to treat COVID-19. Despite its approval, the company could not keep up with the demand due to coronavirus spikes.

Fortunately, as the omicron cases subside, the drug has become readily available to schools and healthcare facilities in the U.S. On a website which the federal government runs, 130,000 courses of Paxlovid are available. Moreover, the website indicates the healthcare providers and pharmacies with the drug.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Duncan Oleinic

Duncan Oleinic is from New Yourk. After graduating with a degree in physics, he began his career as an analyst in a broking firm. Through this experience he was able to advance to the role of correspondent for a U.S based financial news provider, where he worked from 2001 to 2007. He subsequently joined a merchant banking firm as a financial analyst focused on valuing unlisted companies in the sub-continent. Over the course of his two years here, he performed valuations of several media companies which were later acquired by peers.

Recent Stories

SignUp Now For Our Featured Newsletter